Regeneron Pharmaceuticals Inc (REGN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Total Assets Chart for Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc (REGN) total assets for FY2025 were USD 40.6B, a 7.4% change from FY2024. Regeneron Pharmaceuticals Inc's total assets grew from USD 25.4M in 1990 to USD 40.6B in 2025 (159579.9% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 18.8%, 10-year CAGR of 21.9%, 20-year CAGR of 25.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $79.49B
- Implied Share Price
- $785.98
- Enterprise Value
- $73.03B
- Revenue (TTM)
- $15.53B
- EBITDA
- $4.70B
- Profit Margin
- 27.87%
- Trailing P/E
- 19.01
- Forward P/E
- 16.61
- Price/Book (MRQ)
- 2.47
- Price/Sales (TTM)
- 5.12
- EV/EBITDA
- 12.70
- EV/Revenue
- 4.70
- Dividend Yield
- 0.47%
- Book Value
- $316.11
- Free Cash Flow (FY2025)
- $4.08B
- Free Cash Flow Yield
- 5.13%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.